Loading...
•
Sep 30, 2022
Celldex Q3 2022 Earnings Report
Reported financial results and provided a corporate update for Q3 2022.
Key Takeaways
Celldex reported its Q3 2022 financial results, highlighting progress across multiple programs, including the initiation of Phase 2 studies for barzolvolimab in chronic urticaria. The company anticipates data readouts from the barzolvolimab program starting in December and is advancing its bispecific antibody platform with CDX-585 expected to enter the clinic in 2023. Celldex believes its cash is sufficient to fund operations through 2025.
Initiated Phase 2 studies in chronic spontaneous and chronic inducible urticaria.
Anticipate a consistent stream of data readouts from the barzolvolimab program, starting in December.
CDX-585, an ILT4 and PD-(L)1 bispecific antibody, is expected to enter the clinic in 2023.
Cash, cash equivalents and marketable securities as of September 30, 2022 were $323.5 million.
Celldex
Celldex
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.